Coherus Oncology Inc (CHRS) returns
Coherus Oncology returns over 10 years
$1,000 invested in Coherus Oncology ten years ago was worth $28.92 at the close on October 30, 2026, with dividends reinvested: an average return of -29.8% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -31.4% | — | $686.03 | -0.9% |
| 3 months | -43.5% | — | $564.69 | +2.1% |
| Year to date | -41.5% | — | $584.58 | +11.7% |
| 1 year | -51.2% | — | $488.29 | +12.4% |
| 3 years | -72.4% | -34.9% | $275.78 | +88.5% |
| 5 years | -95.0% | -45.2% | $49.62 | +76.0% |
| 10 years | -97.1% | -29.8% | $28.92 | +316.6% |
Coherus Oncology return by calendar year
| Year | CHRS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -41.5% | +11.7% | -53.2% |
| 2025 | +2.9% | +17.7% | -14.8% |
| 2024 | -58.6% | +24.9% | -83.4% |
| 2023 | -58.0% | +26.2% | -84.1% |
| 2022 | -50.4% | -18.2% | -32.2% |
| 2021 | -8.2% | +28.7% | -36.9% |
| 2020 | -3.5% | +18.4% | -21.8% |
| 2019 | +99.0% | +31.2% | +67.7% |
| 2018 | +2.8% | -4.6% | +7.4% |
| 2017 | -68.7% | +21.7% | -90.4% |
| 2016 | +22.6% | +12.0% | +10.6% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: CHRS financials · CHRS valuation
No forecast, no recommendation. This page describes Coherus Oncology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.